Procedure
extracranial, Tumor, extracranial lesions, intracranial target lesions, intracranial lesions, Cancer
DISEASE PROGRESSION, ADVERSE EVENT, TUMOR, ADVERSE EVENTS, CANCER
Patients assigned to the gefitinib-alone group received gefitinib, 250 mg, once daily; patients assigned to the gefitinib plus chemotherapy group received gefitinib, 250 mg, once daily with chemotherapy (pemetrexed, 500 mg/mTumor evaluation for intracranial and extracranial lesions was independently assessed by investigators. The number of intracranial target lesions was extended to 5 lesions, as well as 5 extracranial target lesions according to modified RECIST 1.1 guidelines. Tumor assessments were performed within the 3 weeks before enrollment, then every 8 weeks (enhanced computed tomography scans for extracranial lesions and enhanced magnetic resonance imaging for intracranial lesions) until disease progression was noted. Physical and laboratory examinations were performed within 7 days before enrollment, every 4 weeks during treatment, and at the time of disease progression. After disease progression, follow-up for survival analysis was performed every 3 months. All adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.